Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases. Our first product, JUXTAPID received marketing approval from the U.S. Food and Drug Administration (“FDA”) on December 21, 2012, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein (“LDL”) apheresis, where available, to reduce low-density lipoprotein cholesterol (“LDL-C”), total cholesterol (“TC”), apolipoprotein B (“apo B”) and non-high-density lipoprotein cholesterol (“non-HDL-C”) in patients with homozygous familial hypercholesterolemia (“HoFH”). We launched JUXTAPID in the U.S. in late January 2013. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.58 |
| Quarterly EPS Est: | -0.64 |
| PEG Ratio: | -.03 |
|
Mean Recommendation: View Summary / View All |
1.09 |
Data is provided by Zacks Investment Research

